Flow diverter devices became available in our department in 2009. We considered treatment with flow diverters only in patients with aneurysms not suitable for surgery or conventional endovascular techniques. This paper presents our preliminary experience with flow diverters in a consecutive series of 550 endovascular aneurysm treatments.
Introduction
Flow diverter devices are new tools for the endovascular treatment of intracranial aneurysms. Flow diverters are intended to reconstruct the parent artery carrying the aneurysm. Reconstruction is supposed to occur in such a way that flow is diverted from the aneurysm resulting in disruption of flow and stasis of blood followed by thrombosis. At the same time, important side branches of the artery covered with the flow diverter should remain open 1, 2 . The flow diverter is conceptually appealing to many operators and these devices are being deployed in greater numbers of patients with both simple and complex aneurysm morphologies 3 . However, the safety and efficacy profiles of flow diverters are still poorly understood 4, 5 .
In our department flow diverters became available in 2009. We considered treatment with flow diverters only in patients with aneurysms not suitable for surgery or conventional endovascular techniques such as selective coiling with or without balloon or stent assistance or parent vessel occlusion. This paper presents our preliminary experience with flow diverters available as therapeutic devices. aneurysm on the A1, immediate basal ganglia ischaemia occurred resulting in cognition problems and dysphasia 7 . Follow-up in the surviving ten patients with 11 aneurysms was a mean 12.3 months (range 6-32 months). Eight aneurysms were occluded at three to 12 months with a patent parent artery. Two aneurysms are still open at 12 and 30 months despite placement of an additional Pipeline in one. In the patient with bilateral vertebral dissection aneurysms, the V4 segment of the right vertebral artery was occluded at six months with small infarctions in the medulla oblongata resulting in partial Wallenberg syndrome. At 32 months, the patient presented with haemorrhagic brain stem infarction and died before angiography could be performed.
Representative cases
Case 1, Figure 1 , patient no. 7
An elderly woman was referred for MRI for repeated vertebrobasilar TIAs. Bilateral vertebral dissection aneurysms were evident and angiography was performed showing dissecting aneurysms in close relation with the PICA on both sides. Deconstructive or reconstructive endovascular therapy with coils and stents was judged not possible and in one session Pipelines were placed in the dissecting segments of both vertebral arteries.
Follow-up MRI and angiography showed that the left aneurysm was occluded with a patent vertebral artery. However, the right vertebral artery was completely occluded with a patent PICA. The patient had small infarctions in the medulla oblongata and a partial Wallenberg syndrome. In addition, there were new small peripheral cerebellar infarctions. At 32 months follow-up, the patient presented with extensive haemorrhagic brain stem infarction and died before angiography could be performed. We speculate that late occlusion of the flow diverter in the left vertebral artery was the cause for this event.
Case 2, Figure 2 , patient no.8
A middle-aged man was admitted in good grade SAH from a left vertebral dissection aneurysm. The right vertebral artery had a PICA ending. Conventional reconstructive therapy was not possible. In the following days the patient had two recurrent SAHs and on day 6 a Pipeline device was placed across the dissecting
Materials and Methods
Between January 2009 and July 2013, 550 endovascular treatments for intracranial aneurysms were performed. Of these, 490 were firsttime aneurysm treatments in 464 patients and 61 were additional treatments of previously coiled aneurysms in 51 patients. Endovascular treatments consisted of selective coiling in 445 (80.8%), stent-assisted coiling in 68 (12.4%), balloon-assisted coiling in 13 (2.4%), parent vessel occlusion in 12 (2.2%) and flow diverter treatment in 11 (2.2%).
The 12 aneurysms in 11 patients treated with flow diverters form the subject of this study. All nine unruptured aneurysms were proctored by peers with ample experience with flow diverters. Patients with unruptured aneurysms were preloaded with dual antiplatelet medication. Patients with ruptured aneurysms received 500 mg Aspirin intravenously just prior to flow diverter placement. Dual antiplatelet medication was continued for six months. One patient had bilateral vertebral dissection aneurysms treated with flow diverters. Patient, aneurysm and treatment characteristics are summarized in Table 1. There were seven women and four men aged between 48 and 68 years. There were five large or giant aneurysms of the carotid artery, three presented with symptoms of mass effect and two had been previously coiled. None of the five patients with large or giant carotid artery aneurysms tolerated angiographic test occlusion. There were four dissection aneurysms, one ruptured supraclinoid carotid artery aneurysm and three vertebral dissection aneurysms of which one had ruptured. Two aneurysms were located on the basilar trunk and presented with mass effect on the brain stem and one incidentally found aneurysm was located on the A1.
Results

General results
Four aneurysms were treated with SILK (Balt, Montmorency, France) and eight with the Pipeline device (ev3, Irvine, CA, USA). Two devices were placed in five patients and one device was placed in the other six. In one patient with a basilar trunk aneurysm the procedure was complicated by acute in-stent thrombosis resulting in death 6 . In another patient, with an 
Discussion
When the flow diverter became available for the endovascular treatment of intracranial aneurysms in our hospital the device was welcomed as a promising additional tool for aneurysms with difficult morphology. Since at that time no or little clinical data on efficacy and safety were available, we decided to use the flow diverter only in cases were conventional endovascular techniques or surgery were impossible or undesirable. This restraint indication resulted in only 11 treatments with flow diverters among 550 endovascular treatments in a 4.5 year period. Our preliminary results are disappointing: of ten patients, two died and one had permanent morbidity, and two aneurysms are still open at up to 30 months follow-up.
Our unsatisfactory results in our limited experience with flow diverters seem to be in agreement with other studies. Although some small single centre studies report good results 8, 9 , pooled data from registries and meta-analy-vertebral aneurysm. The patient gradually completely recovered and follow-up angiography at six months showed that the aneurysm had grown and was still open. Further followup is scheduled.
Case 3, Figure 3, patient no. 2
An elderly man was referred for CT scan of the head after a minor trauma and an aneurysm was suspected. Angiography demonstrated a large fusiform aneurysm of the left supraclinoid carotid artery.
A test occlusion of the left internal carotid artery was not tolerated. After several consultations at the outpatient clinic, it was finally decided to treat the aneurysm by placing a Pipeline flow diverter. Follow-up CT angiography at six, 12, 18 and 24 months revealed that the aneurysm was still open and at 24 months a second Pipeline was telescopically placed across the aneurysm. CT angiography six months later showed that the aneurysm is still open. tion aneurysms, flow diversion is predominantly used for large and giant aneurysms of the internal carotid artery and M1 segment. Most of these aneurysms can be treated with conventional endovascular techniques or direct surgery at lower risk and with an equal or better chance of success. Especially in cavernous sinus aneurysms, that generally exhibit a benign clinical course, the treatment complication rate should approach 0%, a safety profile that flow diverters cannot offer. For resolution of symptoms of mass effect, flow diversion is not better than conventional endovascular techniques. Most patients with aneurysms presenting with mass effect do well after conventional endovascular treatment such as selective coiling or parent vessel occlusion [15] [16] [17] [18] .
Since the flow diverter became available in our practice, our initial enthusiasm for the concept of flow diversion has not been sustained. Both our own poor results and the high complication rates reported in the literature have converted our enthusiasm to apprehension and hesitancy 19, 20 . We cannot offer a patient with an unruptured aneurysm a treatment with a more than one in ten chance of mortality or permanent neurological deficit and at the same time with a chance of one in four that the aneurysm does not occlude, at least in the first year. In our view, the indication for a flow diverter is restricted to those unruptured aneurysms with a poor natural history that cannot be treated otherwise. Our initial experience indicates that flow diversion can thus be restricted to less than 2% of all endovascular treatments for aneurysms.
In patients presenting with unruptured aneurysms, our first goal is to do no harm. A treatment strategy with parent vessel occlusion when tolerated, selective coiling when necessary and conservative treatment when possible (cavernous sinus aneurysms) has a very low complication rate approaching 0% and is effective in preventing first-time SAH or in alleviating symptoms of mass effect and has no negative consequences in the long term. With over 10% combined morbidity and mortality together with the risk of delayed aneurysm rupture and delayed parent vessel occlusion, flow diverters should for now be considered a dangerous therapy for unruptured aneurysms, especially for posterior circulation aneurysms. ses indicate complications in a substantial proportion of patients and suboptimal treatment efficacy 4, 5, 10, 11 . In the meta analysis of Brinjikji et al. 5 , comprising 1654 unruptured aneurysms in 1451 patients, treatment mortality was 4% and permanent morbidity was 5%. Complications consisted of early SAH (<30 days) in 3%, late SAH in 2%, early parenchymal haemorrhage in 3% and late in 2%, early ischaemic stroke in 5% and late ischaemic stroke in 3%. Perforator infarction occurred in 3%. SAH occurred more often in large and giant aneurysms and ischaemic events more often in the posterior circulation. At six months, the aneurysm occlusion rate was 76%. Since the cumulative proportion of complications exceeds the overall morbidity and mortality rate in this analysis, apparently many complications occur that do not lead to permanent morbidity or death. Another meta analysis 4 comprising 1018 aneurysms in 897 patients and largely overlapping the Brinjikji study reported an overall mortality rate of 4.1% and neurological morbidity was 9.9%. At a mean follow-up of nine months, 76% of aneurysms were occluded. Both metaanalyses comprised early studies with limited follow-up periods. It remains unknown what proportion of aneurysms will occlude beyond the six to nine months interval. Furthermore, the frequency of late adverse events like late in-stent stenosis and parent vessel occlusion and haemorrhage is unknown but these events will likely increase the overall complication rate of treatment with flow diverters. This issue of late events was addressed by Velioglu et al. 12 , who combined their results with four other studies and found that in more than 11% (22 of 197) of aneurysms treated with a flow diverter the parent artery became occluded during follow-up.
Because of the need for anti aggregation for patients undergoing treatment with a flow diverter, the majority of treatments are performed in patients with unruptured aneurysms. The preliminary results of endovascular treatment of intracranial aneurysms with flow diverters are much worse than for conventional endovascular techniques, in terms of both safety and efficacy 13, 14 . In view of the high ischaemic event rate in posterior circulation aneurysms, the use of flow diverters in this location is strongly discouraged 4, 5 . In anterior circula-
